MA31471B1 - Formulations d'anticorps - Google Patents
Formulations d'anticorpsInfo
- Publication number
- MA31471B1 MA31471B1 MA32460A MA32460A MA31471B1 MA 31471 B1 MA31471 B1 MA 31471B1 MA 32460 A MA32460 A MA 32460A MA 32460 A MA32460 A MA 32460A MA 31471 B1 MA31471 B1 MA 31471B1
- Authority
- MA
- Morocco
- Prior art keywords
- stable
- shear
- temperature
- formulations
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
Abstract
L'invention concerne des formulations d'anticorps stables au cisaillement et à la température, qui sont plus stables qu'une formulation type (telle que citrate à 30 mm, nacl à 100 mm, ph 6,5). Les formulations d'anticorps stables au cisaillement et à la température de la présente invention affichent une précipitation réduite lorsqu'elles sont soumises à des conditions de contrainte, contrairement à la formulation type qui s'agrège. Ce résultat était imprévisible du fait que les deux formulations sont thermodynamiquement similaires, comme qu'observé par leurs profils dsc (calorimètre à balayage différentiel).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94822007P | 2007-07-06 | 2007-07-06 | |
| PCT/US2008/069125 WO2009009407A1 (fr) | 2007-07-06 | 2008-07-03 | Formulations d'anticorps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31471B1 true MA31471B1 (fr) | 2010-06-01 |
Family
ID=40228991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32460A MA31471B1 (fr) | 2007-07-06 | 2009-12-30 | Formulations d'anticorps |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20110020328A1 (fr) |
| EP (2) | EP2889310B1 (fr) |
| JP (1) | JP5529017B2 (fr) |
| KR (2) | KR20100038092A (fr) |
| CN (1) | CN101820912B (fr) |
| AR (2) | AR067455A1 (fr) |
| AU (1) | AU2008275278B2 (fr) |
| BR (2) | BR122020026978B1 (fr) |
| CA (1) | CA2692681C (fr) |
| CL (1) | CL2008001984A1 (fr) |
| CO (1) | CO6270340A2 (fr) |
| CR (1) | CR11249A (fr) |
| CY (3) | CY1118419T1 (fr) |
| DK (2) | DK2170388T3 (fr) |
| DO (1) | DOP2010000001A (fr) |
| EA (1) | EA017994B1 (fr) |
| ES (2) | ES2610821T3 (fr) |
| FR (1) | FR21C1040I1 (fr) |
| HR (2) | HRP20170033T1 (fr) |
| HU (3) | HUE038501T2 (fr) |
| IL (1) | IL202950A (fr) |
| JO (1) | JO3219B1 (fr) |
| LT (3) | LT2889310T (fr) |
| MA (1) | MA31471B1 (fr) |
| MX (1) | MX2010000017A (fr) |
| MY (1) | MY210424A (fr) |
| NO (2) | NO2889310T3 (fr) |
| NZ (1) | NZ582250A (fr) |
| PE (1) | PE20090738A1 (fr) |
| PL (2) | PL2170388T3 (fr) |
| PT (2) | PT2170388T (fr) |
| SI (2) | SI2889310T1 (fr) |
| TR (1) | TR201802928T4 (fr) |
| TW (2) | TWI612060B (fr) |
| UA (1) | UA107557C2 (fr) |
| UY (1) | UY31210A1 (fr) |
| WO (1) | WO2009009407A1 (fr) |
| ZA (1) | ZA200909107B (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| EP2173163A4 (fr) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | Formulations d'anticorps |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| PL2542257T3 (pl) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI) |
| AU2011257219B2 (en) | 2010-05-28 | 2014-12-04 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| EP2694708A4 (fr) * | 2011-04-07 | 2014-10-01 | Glaxosmithkline Llc | Formulations à viscosité réduite |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| CN108969761A (zh) * | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | 抗α4β7抗体的制剂 |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CA3289338A1 (en) * | 2013-03-12 | 2025-11-29 | Primal Therapies, Inc. | Dental composition comprising chelator and base |
| EP2805730A1 (fr) * | 2013-05-21 | 2014-11-26 | Bergen Teknologioverforing AS | Donneurs d'oxyde nitrique pour le traitement du syndrome de fatigue chronique |
| WO2015162504A1 (fr) | 2014-04-23 | 2015-10-29 | Novartis Ag | Nouveau dosage et nouvelles utilisations de l'ofatumumab |
| WO2016189491A1 (fr) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Nouvelle formulation |
| US11285210B2 (en) * | 2016-02-03 | 2022-03-29 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| RS64541B1 (sr) | 2016-08-15 | 2023-09-29 | Novartis Ag | Režimi i postupci za lečenje multiple skleroze upotrebom ofatumumaba |
| WO2018179138A1 (fr) * | 2017-03-29 | 2018-10-04 | 持田製薬株式会社 | Préparation de liquide contenant des anticorps |
| US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| WO2018204374A1 (fr) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11513046B2 (en) * | 2018-02-09 | 2022-11-29 | Championx Usa Inc. | Flowability testing systems and methods |
| BR112021008873A8 (pt) | 2018-11-07 | 2023-04-11 | Merck Sharp & Dohme | Formulação |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| US20220389109A1 (en) | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| LT3864053T (lt) | 2019-09-11 | 2023-09-11 | Novartis Ag | Rms gydymas, pakeičiant terapiją |
| CN112675126A (zh) * | 2019-10-18 | 2021-04-20 | 百奥泰生物制药股份有限公司 | 抗cd20抗体制剂及其应用 |
| EP4682171A2 (fr) | 2020-04-09 | 2026-01-21 | Novartis AG | Ofatumumab pour le traitement de la sclérose en plaques tout en maintenant l'igg sérique |
| US12435154B2 (en) | 2020-05-08 | 2025-10-07 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
| JP7057954B2 (ja) * | 2020-09-03 | 2022-04-21 | 国立大学法人大阪大学 | 改善された保存安定性を有するタンパク質含有液体製剤 |
| EP4323000A1 (fr) | 2021-04-14 | 2024-02-21 | Novartis AG | Ofatumumab pour le traitement de la sclérose en plaques chez des patients asiatiques |
| JP2024531314A (ja) | 2021-08-16 | 2024-08-29 | ノバルティス アーゲー | 小児ｍｓを治療するためのオファツムマブ |
| JP2025513510A (ja) * | 2022-04-20 | 2025-04-24 | アルトス バイオロジックス インク． | オクレリズマブを含む薬学的組成物とその用途 |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025037335A1 (fr) * | 2023-08-12 | 2025-02-20 | Dr. Reddy's Laboratories Limited | Formulations d'anticorps anti-cd20 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1993011161A1 (fr) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Proteines multivalentes de fixation aux antigenes |
| WO1998056418A1 (fr) * | 1997-06-13 | 1998-12-17 | Genentech, Inc. | Formulation stabilisee renfermant un anticorps |
| CN100389821C (zh) * | 1999-10-04 | 2008-05-28 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2003208415B2 (en) | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| PT1946776T (pt) * | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| EP1551875A4 (fr) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | Preparations tamponnees permettant de concentrer des anticorps et procedes pour les utiliser |
| NZ568769A (en) | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
| JP4739763B2 (ja) * | 2002-12-16 | 2011-08-03 | ゲンマブ エー／エス | インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体 |
| US8084582B2 (en) * | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| JP2006249083A (ja) * | 2005-03-08 | 2006-09-21 | Pharmacia & Upjohn Co Llc | 抗ｍ−ｃｓｆ抗体組成物 |
| PL1942939T5 (pl) * | 2005-09-30 | 2021-10-11 | Medimmune Limited | Kompozycja przeciwciała interleukiny-13 |
| EP2173163A4 (fr) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | Formulations d'anticorps |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу |
-
2008
- 2008-03-07 UA UAA201001165A patent/UA107557C2/ru unknown
- 2008-07-03 PT PT87813234T patent/PT2170388T/pt unknown
- 2008-07-03 NO NO15155712A patent/NO2889310T3/no unknown
- 2008-07-03 ES ES08781323.4T patent/ES2610821T3/es active Active
- 2008-07-03 KR KR1020107000148A patent/KR20100038092A/ko not_active Withdrawn
- 2008-07-03 EP EP15155712.1A patent/EP2889310B1/fr active Active
- 2008-07-03 LT LTEP15155712.1T patent/LT2889310T/lt unknown
- 2008-07-03 HU HUE15155712A patent/HUE038501T2/hu unknown
- 2008-07-03 PT PT151557121T patent/PT2889310T/pt unknown
- 2008-07-03 BR BR122020026978-2A patent/BR122020026978B1/pt active IP Right Grant
- 2008-07-03 HR HRP20170033TT patent/HRP20170033T1/hr unknown
- 2008-07-03 MX MX2010000017A patent/MX2010000017A/es active IP Right Grant
- 2008-07-03 CN CN200880105866.1A patent/CN101820912B/zh active Active
- 2008-07-03 DK DK08781323.4T patent/DK2170388T3/en active
- 2008-07-03 EA EA201070105A patent/EA017994B1/ru not_active IP Right Cessation
- 2008-07-03 US US12/667,890 patent/US20110020328A1/en not_active Abandoned
- 2008-07-03 PL PL08781323T patent/PL2170388T3/pl unknown
- 2008-07-03 SI SI200831928T patent/SI2889310T1/en unknown
- 2008-07-03 AU AU2008275278A patent/AU2008275278B2/en active Active
- 2008-07-03 PL PL15155712T patent/PL2889310T3/pl unknown
- 2008-07-03 MY MYPI2010000010A patent/MY210424A/en unknown
- 2008-07-03 BR BRPI0814003-0A patent/BRPI0814003B1/pt active IP Right Grant
- 2008-07-03 KR KR1020157019741A patent/KR101670454B1/ko active Active
- 2008-07-03 SI SI200831738A patent/SI2170388T1/sl unknown
- 2008-07-03 TR TR2018/02928T patent/TR201802928T4/tr unknown
- 2008-07-03 ES ES15155712.1T patent/ES2663504T3/es active Active
- 2008-07-03 NZ NZ582250A patent/NZ582250A/en unknown
- 2008-07-03 DK DK15155712.1T patent/DK2889310T3/en active
- 2008-07-03 CA CA2692681A patent/CA2692681C/fr active Active
- 2008-07-03 HU HUE08781323A patent/HUE031288T2/hu unknown
- 2008-07-03 WO PCT/US2008/069125 patent/WO2009009407A1/fr not_active Ceased
- 2008-07-03 EP EP08781323.4A patent/EP2170388B1/fr active Active
- 2008-07-03 JO JOP/2008/0312A patent/JO3219B1/ar active
- 2008-07-03 LT LTEP08781323.4T patent/LT2170388T/lt unknown
- 2008-07-03 JP JP2010516158A patent/JP5529017B2/ja active Active
- 2008-07-04 TW TW104128324A patent/TWI612060B/zh active
- 2008-07-04 CL CL2008001984A patent/CL2008001984A1/es unknown
- 2008-07-04 PE PE2008001136A patent/PE20090738A1/es active IP Right Grant
- 2008-07-04 AR ARP080102910A patent/AR067455A1/es unknown
- 2008-07-04 UY UY31210A patent/UY31210A1/es not_active Application Discontinuation
- 2008-07-04 TW TW097125246A patent/TWI515204B/zh active
-
2009
- 2009-12-21 ZA ZA2009/09107A patent/ZA200909107B/en unknown
- 2009-12-24 IL IL202950A patent/IL202950A/en active IP Right Grant
- 2009-12-30 CO CO09149371A patent/CO6270340A2/es active IP Right Grant
- 2009-12-30 MA MA32460A patent/MA31471B1/fr unknown
-
2010
- 2010-01-05 DO DO2010000001A patent/DOP2010000001A/es unknown
- 2010-02-02 CR CR11249A patent/CR11249A/es unknown
-
2015
- 2015-02-19 US US14/625,881 patent/US20150158951A1/en not_active Abandoned
-
2017
- 2017-01-12 CY CY20171100043T patent/CY1118419T1/el unknown
- 2017-08-29 AR ARP170102392A patent/AR109461A2/es not_active Application Discontinuation
-
2018
- 2018-03-14 HR HRP20180440TT patent/HRP20180440T1/hr unknown
- 2018-03-20 CY CY20181100325T patent/CY1120047T1/el unknown
-
2021
- 2021-09-13 NO NO2021036C patent/NO2021036I1/no unknown
- 2021-09-14 CY CY2021027C patent/CY2021027I2/el unknown
- 2021-09-14 FR FR21C1040C patent/FR21C1040I1/fr active Active
- 2021-09-15 LT LTPA2021520C patent/LTPA2021520I1/lt unknown
- 2021-09-15 HU HUS2100038C patent/HUS2100038I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31471B1 (fr) | Formulations d'anticorps | |
| MA31502B1 (fr) | Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation | |
| PL410219A1 (pl) | Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca | |
| MA31898B1 (fr) | Compositions pharmaceutiques | |
| MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
| BRPI0513959A (pt) | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos | |
| EP2130552A4 (fr) | Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif | |
| EP2093237A4 (fr) | Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif | |
| EP2066350A4 (fr) | Formulations stabilisees d'anticorps et leurs utilisations | |
| AR074427A1 (es) | Composiciones estables de anticuerpos y metodos para estabilizarlas | |
| WO2006096488A3 (fr) | Compositions d'anticorps en plateau | |
| MA29975B1 (fr) | Antagonistes de la neuropiline | |
| JO3417B1 (ar) | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r | |
| MA31437B1 (fr) | Polypeptides, domaines variables d'anticorps et antagonistes | |
| EP2121008A4 (fr) | Utilisations de l'anticorps monoclonal 8h9 | |
| MA31519B1 (fr) | Compositions d'immunoglobulines lyophilisées et procédés de préparation | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| MA31984B1 (fr) | Formulation d'anticorps | |
| MA30474B1 (fr) | Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee. | |
| EA200800355A1 (ru) | Нейтрализующие антитела человека против b7rp1 | |
| MA33541B1 (fr) | Nouvelles compositions biopesticides et leur procédé d'isolement et de caractérisation | |
| MA33221B1 (fr) | Fusions de médicament et conjugués afférents | |
| MA35009B1 (fr) | Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci | |
| MA29459B1 (fr) | Vaccins | |
| DK1720909T3 (da) | Anti-Abeta antistof |